Drugs / RC118
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04914117 | Nov 2021 → Nov 2022 | metastatic neoplasm | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06038396 | Aug 2023 → Feb 2026 overdue | neoplasm | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-12-20 | RemeGen Co., Ltd. | Results RemeGen RC118 phase I clinical study shows favorable safety and tolerability remegen.com ↗
Preliminary clinical studies have shown that no dose limiting toxicity (DLT) events have been observed in clinical trials conducted in China and Australia, indicating that RC118 is safe and well tolerated in both Chinese and Australians. |
| 2021-07-30 | RemeGen Co., Ltd. | Regulatory First clinical trial permit in Australia of Remegen! RC118, an ADC drug targeting the Claudin18.2 remegen.com ↗
On July 30th, Remegen announced that it has received an ethical approval from the Australian Human Research Ethics Committee for the phase I clinical trial of antibody-drug conjugate (ADC) RC118. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-20 | RemeGen Co., Ltd. | RemeGen RC118 phase I clinical study shows favorable safety and tolerability remegen.com ↗ |
| 2021-12-01 | RemeGen Co., Ltd. | First patient enrolled in RC118 phaseⅠclinical trial in Australia by RemeGen! RC118, an ADC drug targeting Claudin18.2 remegen.com ↗ |
| 2021-07-30 | RemeGen Co., Ltd. | First clinical trial permit in Australia of Remegen! RC118, an ADC drug targeting the Claudin18.2 remegen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04914117 ↗ |
| Route | Intravenous | “RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.” NCT04914117 ↗ |